X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1922) 1922
Publication (118) 118
Newsletter (95) 95
Newspaper Article (24) 24
Book Review (22) 22
Conference Proceeding (4) 4
Magazine Article (4) 4
Book Chapter (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1559) 1559
formoterol fumarate (1463) 1463
male (985) 985
formoterol (965) 965
female (882) 882
asthma - drug therapy (849) 849
ethanolamines - administration & dosage (798) 798
index medicus (766) 766
administration, inhalation (749) 749
asthma (723) 723
adult (705) 705
middle aged (700) 700
respiratory system (693) 693
ethanolamines - therapeutic use (641) 641
bronchodilator agents - administration & dosage (640) 640
bronchodilator agents - therapeutic use (497) 497
aged (487) 487
double-blind method (475) 475
treatment outcome (452) 452
pulmonary disease, chronic obstructive - drug therapy (425) 425
drug combinations (424) 424
salmeterol (400) 400
budesonide (389) 389
drug therapy, combination (384) 384
budesonide - administration & dosage (364) 364
albuterol - analogs & derivatives (349) 349
pharmacology & pharmacy (341) 341
adolescent (337) 337
ethanolamines - pharmacology (336) 336
salmeterol xinafoate (305) 305
ethanolamines - adverse effects (297) 297
drug therapy (282) 282
albuterol - therapeutic use (275) 275
adrenergic beta-agonists - therapeutic use (267) 267
budesonide - therapeutic use (262) 262
asthma - physiopathology (258) 258
copd (251) 251
albuterol - administration & dosage (243) 243
bronchodilator agents - adverse effects (242) 242
dose-response relationship, drug (240) 240
lung diseases, obstructive (236) 236
adrenergic beta-agonists - administration & dosage (232) 232
obstructive pulmonary-disease (232) 232
child (227) 227
cross-over studies (227) 227
nebulizers and vaporizers (226) 226
time factors (220) 220
animals (215) 215
salbutamol (212) 212
forced expiratory volume - drug effects (211) 211
chronic obstructive pulmonary disease (206) 206
anti-asthmatic agents - administration & dosage (201) 201
forced expiratory volume (201) 201
efficacy (194) 194
exacerbations (190) 190
corticosteroids (189) 189
pulmonary disease, chronic obstructive - physiopathology (187) 187
safety (178) 178
adrenergic beta-agonists - pharmacology (174) 174
metered dose inhalers (171) 171
bronchodilator agents - pharmacology (170) 170
fluticasone (168) 168
adrenergic beta-2 receptor agonists - administration & dosage (165) 165
pulmonary and respiratory medicine (162) 162
dosage and administration (157) 157
drug administration schedule (157) 157
adrenal cortex hormones - administration & dosage (154) 154
care and treatment (152) 152
respiratory tract diseases (152) 152
anti-asthmatic agents - therapeutic use (148) 148
cardiac & cardiovascular systems (148) 148
research (148) 148
aged, 80 and over (146) 146
allergy (144) 144
pulmonary/respiratory (144) 144
randomized controlled trials as topic (143) 143
medicine, general & internal (141) 141
formoterol fumarate - administration & dosage (137) 137
albuterol - pharmacology (135) 135
steroids (135) 135
young adult (135) 135
budesonide/formoterol (133) 133
quality of life (128) 128
antiasthmatic agents (127) 127
respiratory function tests (126) 126
analysis (124) 124
clinical trials (124) 124
single inhaler (124) 124
inhaled corticosteroids (122) 122
therapy (122) 122
severity of illness index (120) 120
adrenal cortex hormones - therapeutic use (119) 119
immunology (119) 119
adrenergic beta-agonists - adverse effects (118) 118
fluticasone propionate (114) 114
androstadienes - administration & dosage (112) 112
tiotropium (112) 112
budesonide - adverse effects (111) 111
double-blind (110) 110
glucocorticoids - administration & dosage (107) 107
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1923) 1923
German (50) 50
Japanese (14) 14
French (12) 12
Spanish (12) 12
Polish (8) 8
Chinese (7) 7
Danish (5) 5
Russian (4) 4
Turkish (3) 3
Czech (2) 2
Portuguese (2) 2
Romanian (2) 2
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Respiratory Research, ISSN 1465-9921, 01/2017, Volume 18, Issue 1, p. 8
Journal Article
Journal Article
Journal Article
Respiratory Medicine, ISSN 0954-6111, 05/2018, Volume 138, pp. 74 - 80
This study compared the efficacy, pharmacokinetics (PK), and safety of GFF MDI (Bevespi Aerosphere ), a fixed-dose combination of glycopyrronium and formoterol... 
Co-suspension delivery technology | Metered dose inhaler | Formoterol fumarate dihydrate | Spacer | Valved holding chamber | Glycopyrronium | LUNG | CARDIAC & CARDIOVASCULAR SYSTEMS | CO-SUSPENSION(TM) DELIVERY TECHNOLOGY | DEPOSITION | COMBINATION | CHILDREN | RESPIRATORY SYSTEM | SPACER DEVICES | ASTHMA | COPD | Bronchodilator Agents - blood | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Pulmonary Disease, Chronic Obstructive - blood | Metered Dose Inhalers | Female | Bronchodilator Agents - adverse effects | Muscarinic Antagonists - blood | Formoterol Fumarate - blood | Glycopyrrolate - adverse effects | Severity of Illness Index | Inhalation Spacers | Formoterol Fumarate - adverse effects | Glycopyrrolate - blood | Muscarinic Antagonists - administration & dosage | Glycopyrrolate - administration & dosage | Aged | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Chlorofluorocarbons | Parameters | Lung diseases | Pharmacology | Glycopyrrolate | Patients | Confidence intervals | Randomization | Concentration time | Obstructive lung disease | Formoterol | Chronic obstructive pulmonary disease | Safety | Pharmacokinetics | Drug dosages
Journal Article
Journal Article
Respiratory research, ISSN 1465-9921, 2014, Volume 15, Issue 1, pp. 123 - 123
Background: Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic... 
Formoterol | Dyspnea | Health status | Lung function | Aclidinium | COPD | MODERATE | HYPERINFLATION | BRONCHODILATION | MAINTENANCE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TIOTROPIUM | BROMIDE | ACCORD COPD | FLUTICASONE | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | North America | Recovery of Function | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Female | Bronchodilator Agents - adverse effects | Tropanes - administration & dosage | Pulmonary Disease, Chronic Obstructive - diagnosis | Tropanes - adverse effects | Dry Powder Inhalers | Double-Blind Method | Drug Administration Schedule | Formoterol Fumarate - adverse effects | Administration, Inhalation | Treatment Outcome | Dyspnea - physiopathology | Lung - physiopathology | New Zealand | Muscarinic Antagonists - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Aged | Australia | Health Status | Drug Combinations | Formoterol Fumarate - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Pharmaceutical industry | Medical research | Studies | Heart attacks | Laboratories | Smooth muscle | Chronic obstructive pulmonary disease | Drug therapy | Research
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 2017, Volume 42, pp. 43 - 51
Journal Article